Lupin

Lupin Current Liabilities

The Current Liabilities of Lupin (LUPIN.NS) as of Oct 11, 2026 is 126.51 B INR. In the previous year, Current Liabilities was 91.40 B INR — a change of 38.41% (higher).

Current Liabilities

126.51 BINR

YoY

38.41%

Last updated:

Current Liabilities of Lupin is 2026 126.51 B INR. Current Liabilities of Lupin was 2025 91.40 B INR. It decreases by 38.41% higher compared to the previous year.

The Lupin Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
65.80 B INR
Jan 1, 2020
112.52 B INR
Jan 1, 2021
103.80 B INR
Jan 1, 2022
82.28 B INR
Jan 1, 2023
92.32 B INR
Jan 1, 2024
85.45 B INR
Jan 1, 2025
91.40 B INR
Jan 1, 2026
126.51 B INR
The Lupin Current Liabilities history
YEARCurrent LiabilitiesYoY
126.51 BINR+38.41%
91.40 BINR+6.96%
85.45 BINR-7.43%
92.32 BINR+12.20%
82.28 BINR-20.74%
103.80 BINR-7.75%
112.52 BINR+71.00%
65.80 BINR+18.19%
55.67 BINR-12.73%
63.79 BINR+17.17%
54.44 BINR+40.22%
38.83 BINR+49.99%
25.89 BINR-14.04%
30.11 BINR-8.22%
32.81 BINR+6.38%
30.84 BINR+158.22%
11.94 BINR-10.71%
13.38 BINR+78.03%
7.51 BINR+76.88%
4.25 BINR+6.03%
4.01 BINR+26.31%
3.17 BINR+1.04%
3.14 BINR+13.25%
2.77 BINR+71.22%
1.62 BINR-2.23%
1.66 BINR+17.28%
1.41 BINR+52.32%
927.00 MINR—
Access this data via the Eulerpool API
Get Free API Key

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Current Liabilities of Lupin is 126.51 B INR in 2026.

Current Liabilities of Lupin changed from 91.40 B INR to 126.51 B INR, representing a 38.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Lupin since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Lupin historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Lupin

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Lupin